Remicade use extended

The licence for Remicade (infliximab) has been extended to include the treatment of Crohn's disease in paediatrics.

Remicade may be used in children aged six to 17 years unresponsive or intolerant to corticosteroid, immunosuppressant and primary nutrition therapy.

Further information: Schering-Plough 01707 363636

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more